

The Recombinant Production of Novel Bovine Lactoferricin Engineered Peptide Using Molecular Dynamic Simulation

Maryam Akbari Azam¹, Abbasali Matlebi^{*2}, Mohammadreza Nassiri^{*3}, Amirali Anvar⁴

^{1,2,4} Department of Food Hygiene, Science and Research Branch, Islamic Azad University, Tehran, Iran.

^{3*} Department of Animal Science, Faculty of agriculture, Ferdowsi university of Mashhad, Iran.

* Corresponding author:

Mohammadreza Nassiri, Email: mohammadreza.nassiri@newcastle.edu.au, Tel: 09153114119 and

Abbasali Matlebi, Email: motalebi@ifro.ir, Tel:09122995881.

Abstract

Antimicrobial peptides (AMPs) are native and safe short peptides that are considered one of the best alternatives for antibiotics. Although numerous studies have been conducted on AMPs, their mode of action has not yet been fully understood. Computational peptide engineering can provide valuable insight into the stability and potency of AMPs against targets. In the present study, we performed a molecular dynamics simulation study to understand the mode of action of Bovine Lfcin and to improve the interactions between Bovine Lfcin (wild and mutant types) and DNA (an important intracellular target), DNAK (an important protein in pathogenicity, mostly in gram-negative bacteria), and LysM (an important surface protein in gram-positive bacteria). The nucleotide sequence of Lfcin peptide was synthesized and cloned in pET22b(+). Induction of gene expression was done using 1mM IPTG and recombinant peptide was purified using His-tag marker. The antimicrobial peptide activity was performed on *Escherichia coli* O157 and *Bacillus subtilis* Gram- negative and positive bacteria using disk diffusion methods, respectively. Our results showed that all the changes in Bovine Lfcin wild type observed in this study improved the peptide-DNA, DNAK, and LysM interactions. Based on the results, removing the PHE25 residue from the wild type Bovine Lfcin peptide had more significant effects on complex formation with DNA, DNAK, and LysM. The recombinant production of a Lfcin peptide with a molecular weight

of ~5 KDa was confirmed by SDS PAGE. The performance of Lfcin peptide on pathogenic bacteria was strong and it had the strongest effect in concentrations of 6 and 8 mg/ml for gram positive and negative bacteria, respectively.

31

32 **Key words**

33 Antimicrobial peptides, Bovine Lfcin; Recombinant Protein.

34

35

36 **1. Introduction**

37 Lactoferrin is one of the most important milk proteins, and the peptides produced from it
38 are among the strongest AMPs (1). The cationic lactoferrin molecule interacts with a part of
39 lipopolysaccharide (LPS) called lipid A through the positively charged cluster in the N-terminal
40 region of the N-lobe as part of the outer membrane of gram-negative bacteria (2). This interaction
41 causes damage in the cell membrane, the result of which is the permeability and release of LPS.
42 Experiments on human lactoferrin show that the N-terminal part of lactoferrin (lactoferrin regions
43 28-34) plays an essential role in the binding of lactoferrin to LPS (28-30) (3). Studies show that
44 bovine lactoferrin causes damage to the outer membrane of gram-negative bacteria by binding
45 with LPS (4). Investigation of membrane dialysis shows that when metal-saturated or unsaturated
46 lactoferrin is separated from bacterial cells, LPS is also separated from the bacterial outer
47 membrane (2). The interaction of hydrophobic and basic amino acids with the inner core of LPS
48 (especially tryptophan and arginine) result in the antimicrobial activity of lactoferrin (5). This
49 interaction disrupts the structure of the outer membrane and facilitates the binding of tryptophan
50 to lipid A (6). Studies showed that lactoferrin exhibits broad antimicrobial activity against
51 bacterial, viral, and fungal pathogens (7,8).

52 The resistance of pathogenic bacteria to common antimicrobial agents has become a
53 serious threat to human public health (9). This is mainly due to the overuse of antimicrobial agents
54 and overtreatment of medicine (10). Antimicrobial peptides (AMPs) are an innate defense against
55 natural microbial attacks produced by the organism's immune system (11). AMPs have several

biological functions, including antibacterial, antiviral, antiparasitic, antifungal (8). In addition, the multifunctional mechanisms of AMPs reduce the potential to develop resistance against bacteria (12). The physicochemical properties of AMPs such as: amphipathicity, peptide amino acid structure and amino acid sequence, electrical charge, and oligomerization are highly effective in the peptide action mechanism (13). Characteristics such as hydrophobicity and selective destruction of the cell membrane play a vital role in the performance of AMPs(14,9). Thus, the distribution of electric charge on the peptide and the presence of polar phospholipid heads are the most important factors in binding the peptide to the membrane (13). For example, hydrophobic peptides are able to recognize anionic lipids on the outer surface of the bacterial membrane, while in eukaryotic cells, these lipids are located inside the cytoplasmic membrane (15,16). However, in order to induce bacterial death through pore formation, three main processes must occur: 1. binding of AMPs to the bacterial membrane, 2. their accumulation inside the membrane, and 3. peptide insertion and membrane permeability (17). The binding of AMPs to the membrane of bacteria with a negative charge does not have a specific receptor (18). Therefore, the binding of peptides to the bacterial membrane occurs up to a certain molecular concentration, then they penetrate into the cell through several mechanisms (18). However, peptides may interact specifically with one of the membrane components, such as lantibiotics, which bind to lipid II and prevent wall cell production (19).

There are various methods such as microscopic fluorescence polarization, model membranes study, fluorescent dye, ion channel formation and molecular dynamics to investigate the mechanism of AMPs(20, 21). Among these, the molecular dynamics method is one of the most effective and least costly methods in the process of investigating the effect of AMPs(22). The basic problem in understanding the behavior and mechanism of action of these peptides is the lack of information in molecular and atomic dimensions. Normally, tracking the behavior of these peptides in living cells with molecular resolution is very difficult and expensive (23). The number of peptides that can be generated is high, and the vast majority of experimental methods mentioned above are static and lack the ability to interpret the dynamic behavior of these macromolecules (22). Recombinant peptides with high capability and even specificity can be created through understanding their interaction mechanism. Therefore, this study aimed to apply molecular dynamics simulation for engineering broad spectrum antimicrobial peptides. Also, the

86 corresponding sequence was converted into recombinant antimicrobial peptide in *E. coli*, and its
87 effect was investigated on gram-positive and negative bacteria.

88 **2. Material and Methods**

89 **Molecular Dynamic Simulation**

90 **Structure preparation**

91 Three-dimensional B-forms of DNA, DNAK and Bovine Lfcin peptide were obtained from Protein
92 Data Bank with 1BNA, 1DKX and 1LFC accession numbers, respectively. Due to the lack of the
93 three-dimensional structure of the LysM protein in the Protein Data Bank, LysM structure was
94 modeled in Modeller 9.2 software (24). The quality of the LysM model was investigated with
95 PROCHECK server (<http://servicesn.mbi.ucla.edu/PROCHECK/>) (25).

96 **Molecular Dynamics Simulations**

97 The dynamic behavior of the complexes including DNA-Lfcin, DNAK-Lfcin, and LysM-Lfcin
98 were studied using GROMACS 2018 package with periodic boundary conditions in all directions
99 (26) CHARMM27 force field was used for DNA-Lfcin and Gromos54a7 was used for DNAK-
100 Lfcin, and LysM-Lfcin (27). A Simple Point Charge (SPC) water model was used to solvate the
101 system in the cubic water box (28). To neutralize the overall charge of the systems, Na and Cl ions
102 were added by substituting the water molecules. Energy minimization of the systems was
103 performed using steepest descent algorithm. Subsequently, the system was equilibrated under NVT
104 ensemble at 300 K during 400 ps and then continued by an NPT equilibration run at 1 bar pressure
105 and 300 K temperature for 1000ps. Nosé-Hoover algorithm with a time constant of 0.1 ps and
106 Parrinello-Rahman algorithm with a time constant of 0.5 ps were used for coupling the temperature
107 and pressure, respectively (29). LINCS algorithm was used to constrain all bonds. In treating long-
108 range electrostatic interactions, the Particle Mesh Ewald (PME) algorithm was applied. The
109 nonbonded cutoff of 12 Å was also used. MD production runs were carried out for 50,000 ps under
110 NPT ensemble at 1 bar and 310 K. Dynamics and stability of each peptide and BDNA, including
111 root mean square deviation (RMSD), root-mean-square-fluctuations (RMSF) hydrogen bonds
112 were analyzed during the simulation using GROMACS built-in tools.

113 G-MMPBSA program was used for binding free energy estimation. The average binding energy
114 and its standard deviation were calculated using the MmPbSaStat.py python script

115 (http://rashmikumari.github.io/g_mmpbsa/). To estimate the contribution of each residue to the
116 total binding free energy, the MmPbSaDecomp.py python script was used (30).

117 **Production of Lfcin peptide**

118 **Gene Synthesis and Production of Recombinant Protein**

119 The pel B signal sequence was used at the beginning of the structure for periplasmic protein
120 production (31). The Lfcin peptide was codon-optimized for *E. coli* expression and synthesized in
121 a pGH vector by the GenRay Biotechnology (Shanghai, China). The target genes in pGH vector
122 were sub-cloned and then cloned into the pET22b (+) expression vector between *Xba I* and *Hind*
123 *III* restriction sites. *E. coli* BL 21DE3 cells containing recombinant pET22b (+) were cultured in
124 LB broth medium overnight at 37°C and shaken at 180 rpm. Next, 200 ml of overnight culture was
125 inoculated in 2L of LB broth containing 100 µg/ml ampicillin. Then, the culture was allowed to
126 grow at 37°C until optical density (OD) was reached at 600 nm. For induction of expression,
127 isopropyl β-D- thiogalactoside (IPTG) was added to the culture to a final concentration of 1.5 mM.
128 Then, the culture was incubated at 37°C for 5 h. To collect the induced cells, the cells were
129 centrifuged at 12,000 × g for 20 min at 4 °C, and the supernatant was discarded. The supernatant
130 was first analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).

131 **Protein Extraction and Sepharose Chromatography**

132 To extract the proteins, osmotic shock methods were applied (32). Briefly, the 25 ml of
133 hypertonic buffer (Tris-Hcl 30mM, EDTA 1 mM and Saccharose 20%, pH=8) was added to the
134 induced cells and the solution was incubated on ice for 30 min. The solution was centrifuged at
135 8000 g for 20 min and the supernatant was collected. Then, the pellet was suspended in 25 ml of
136 hypotonic 5 mM MgSo4. The solution was incubated for 30 min on ice and centrifuged at 8000 g
137 for 20 min. The supernatants from the hypertonic and hypotonic solutions were mixed and the
138 mixture was dialyzed in lysis solution (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH:
139 8.0) for 16 h. In order to condense the proteins, the solution was filtered by Amicon Ultra-0.5 mL
140 (Merck, USA). Q-sepharose chromatography was used to extract the target protein. Briefly, the Q-
141 Sepharose column was first washed by lysis solution three times, and 5 ml of the supernatant
142 containing soluble recombinant protein was filtered three times at 4 °C. Next, the lysis solution
143 was washed with six dosages of NaCl concentration (0.1, 0.2, 0.3, 1, 2, 3 Molar) in the Q-

144 Sepharose column. Then, the solution was collected for the SDS-PAGE analysis. To extract the
145 target protein, the best concentration of NaCl was used for the entire amount of the soluble
146 recombinant proteins based on SDS-PAGE. Finally, Bradford protein assay was used to determine
147 the protein concentration (33).

148 **Investigation of Lfcin peptide effect on gram-positive and negative bacteria**

149 One of the simple tests to evaluate the antimicrobial activity of a peptide is the disk
150 diffusion method (34). The five different disks were coated with five different concentrations of
151 antimicrobial peptide and then placed on the culture media of gram-positive *Bacillus subtilis* and
152 gram-negative *Escherichia coli* O157. The Gentamycin antibiotic was used as control.

153 **Statistical analysis**

154
155
156

157 **3. Result**

158 **Molecular dynamics simulation**

159 After homology modeling, the structure of the LysM protein was examined for overall
160 quality. Ramachandran plot for LysM protein showed that 93.3% of the residues were situated
161 within the most favored region, while the remaining residues were found within the additional
162 allowed region (Fig1).

163 **Dynamics behavior and interaction between DNA, DNAK, LysM and Bovine Lfcin**

164 RMSD is a measure of how much the protein structure changes compared to the initial structure
165 over the course of the simulation. The RMSD patterns of Bovine Lfcin in interaction with DNA,
166 DNAK and LysM did not deviate drastically over 50,000 ps in all simulations (Fig 2). Dynamic
167 behavior of individual amino acid residues for Lfcin was analyzed using the RMSF value which
168 was defined by the peak elevation in all simulations. Rational behavior of residue fluctuation was
169 observed for Lfcin. The radius of gyration (Rg) shows the compactness of the protein. The plot of

Commented [MB1]:

170 Rg for Lfcin during interaction with DNA, DNAK and LysM was illustrated for alpha-carbon
171 atoms vs time at 310 K (Fig 2). Rg plot for Lfcin during interaction with DNA, DNAK and LysM
172 showed the peptide did not exhibit a major change in Lfcin compactness.

173 **Number of hydrogen bonds**

174 The number of hydrogen bonds between Lfcin and DNA showed significant variation
175 during simulation (Fig 3A). The average number of hydrogen bonds between Lfcin and DNA
176 during 50 ns simulation was 5.76 ± 0.5 ($P < 0.05$). A representative snapshot of the Lfcin-DNA
177 interaction is illustrated in Fig 3B. In this frame, it can be observed that Arg and Glu have
178 hydrogen-bonding with DNA-backbone phosphate groups. The average number of hydrogen
179 bonds between Lfcin and DNAK during 50,000 ps simulation was 9.72 ± 0.3 ($P < 0.05$). The most
180 important region of DNAK for interaction with targets is the aD-aE region. The results showed
181 that Lfcin, on average, had only two hydrogen bonds with this site (Fig 3C). The results indicated
182 that the interaction between Lfcin and LysM are weak (Fig 2D) (two hydrogen bonds on average).

183

184

185

186

187 **Binding Free Energy Estimate**

188 The binding free energy was calculated by the MM/PBSA method. The results revealed that the
189 free binding energy between Lfcin and DNA and DNAK was -342 ± 9.21 and -426 ± 8.24 kJ/mol,
190 respectively ($P < 0.05$). The free energy values for the Lfcin-DNA system were decomposed into
191 residue contributions using the MmPbSaDecomp.py python script. The results suggested that
192 positive charge residues are more relevant for binding (Fig 4A and B). On the other hand, the last
193 residue of Lfcin-DNAK (PHE25) had a detrimental effect on interacting with DNA (Fig 4B). The
194 complex formation and stability in LysM and Lfcin were highly correlated with electrostatic
195 interaction (Fig 4C). The binding energy contribution per amino-acid residue indicates that ARG,
196 LYS, TRP and LEU residues in the bovine Lfcin peptide play a major role in interaction with
197 LysM over 50,000 ps simulation. Overall, in this system, complex stability was mainly due to
198 electrostatic interaction.

199

200 Peptide Engineering

201 Given that the interaction between DNA, DNAK and LysM with Bovine Lfcin was strong,
202 engineering of the Lfcin peptide was carried out. The last amino acid in the Lfcin (PHE25) over
203 interaction with the DNA and DNAK had the highest inhibitory effect. The PHE25 was substituted
204 with ALA amino acid. The results of the binding energy contribution per amino-acid indicate that
205 substitution of PHE with ALA in the last position of the peptide in all targets did not affect complex
206 formation and the change could not improve the free binding energy (Fig 5).

207 Production of Recombinant Lfcin

208 The production of Lfcin antimicrobial peptide was confirmed by SDS PAGE (Fig 6).
209 Protein purification was successfully performed using osmotic shock in the Q-Sepharose column
210 (Fig 6). Although our findings confirmed protein expression, no recombinant proteins were
211 observed in the LB medium, indicating that almost all Lfcin AMPs were expressed either inside
212 the bacterial cell or moved into the periplasmic area. According to the Bradford analysis, the
213 concentration of the recombinant proteins extracted was 10.78 mg/ml for Lfcin antimicrobial
214 peptide ($P < 0.05$).

217 Cytotoxicity of Lfcin for Positive and Negative Bacteria

218 The effect of the peptide on gram-positive and gram-negative bacteria with disk diffusion
219 method (DDM) showed that at a concentration of 6 mg/ml this peptide has the ability to inhibit the
220 growth of *E. coli* O157 and 8 mg/ml for *Bacillus subtilis* ($P < 0.05$). The diameter of the disk radius
221 of a clear zone on media plate indicated the inhibiting effect of Lfcin on bacteria growth (Fig 6).

222 4. Discussion

223 Antibiotic resistance (AMR) is a pervasive global issue that leads to 700.000 fatalities per year
224 worldwide (35). Scientists believe that antibiotic resistance could lead to the death of 10 million
225 people by 2050 (36). A comprehensive review of studies shows that AMPs have a broad-spectrum
226 and the strongest effect against gram-positive and gram-negative bacteria (37-39). Today, AMP

mechanism of action can be predicted using molecular dynamics (MD) simulations (40, 41). MDS studies on AMPs have led to several important products (42-44) and it has been shown that the use of this technique can lead to the discovery of new paths (22).

The BDNA, DNaK and LysM were targets of gram-negative and positive bacteria in engineering of antimicrobial peptides in this study. The B-DNA is the most important and abundant pattern of DNA in nature that is found in gram-negative and positive bacteria (45). The DNaK is a heat shock protein in membrane of gram negative bacteria that plays a major role in pathogenic bacteria (46). This protein is a highly important target in design of AMPs. LysM is a surface protein in gram-positive bacteria and is important to keep bacteria alive. Studies reveal that LysM blocking can destroy bacteria (47). The results of MDS showed that mutant Lcf successfully interacts with DNA, DNA and LysM that confirms Lcf can be classified in broad spectrum AMPs against gram-negative and positive bacteria. Rizzetto et al (2023) reported similar results about the effect of antimicrobial peptides against gram-positive and negative bacteria (48). None of the AMPs in this study were able to destroy gram-positive and gram-negative bacteria in a native state. However, reports show that various mammalian lactoferrins are highly suitable candidates as antimicrobial peptides (49).

AMPs can consist of 10-50 amino acids with smaller AMPs being more effective (50). The molecular weight of Lcf is about 5 KDa with a residue of restriction enzyme and pET vectors. It is expected that the performance of the peptide will be improved by removing the excess amino acids.

The antimicrobial potency of Lcf on *E. coli* and *B. subtilis* was assessed in this study. The results showed that Lcf had great ability to destroy gram-negative than gram-positive bacteria. Therefore, the amphipathicity of the peptide is a more effective parameter (51) Other important parameters are hydrophobicity and hydrophilicity (52). Chen et al (2020) investigated the effect of Chol-37(F34-R) peptide on *Staphylococcus aureus* (gram-positive) and *Salmonella typhimurium* (gram-negative) (51). They showed that Chol-37 peptide has a more significant effect on gram-positive bacteria. The effect of their peptide on *S. aureus* was 64 times stronger than on *S. typhimurium*, while the strength of Lcf peptide was only 1.3 times stronger. These comparisons showed that Lcf peptide has a similar effect on gram-positive and negative bacteria and confirmed that Lcf is a board spectrum AMP. The main purpose of this study was to investigate the interaction of Bovine

۲۵۷ Lfcin as one of the derived peptides of bovine lactoferrin with DNA, DNAK, and LysM protein
۲۵۸ as the main targets of AMPs and antibiotics in gram-negative and positive bacteria. To achieve
۲۵۹ this objective, we performed molecular dynamics simulations. The results indicated that Lfcin had
۲۶۰ weak interaction with these targets. Base on our findings, hydrogen plays a crucial role in the
۲۶۱ formation and stabilization of the Lfcin and targets interaction. To improve the effectiveness of
۲۶۲ this peptide, we opted to change some residues in the Lfcin. Our findings demonstrated that
۲۶۳ removal of the PHE25 in the last position of the Lfcin could cause an increase in the antimicrobial
۲۶۴ effect of the peptide. Our findings in the present study provided valuable information regarding
۲۶۵ the significance of residues in AMPs and could be of considerable value in the field of peptide
۲۶۶ engineering to achieving stronger and higher spectrum AMPs with intra-cellular activity.
۲۶۷

۲۶۸ **Ethics**

۲۶۹ The authors of this study hereby declare that all the ethical standards were followed in the
۲۷۰ procedure of preparing the submitted article.

۲۷۱ **Conflicts of interest**

۲۷۲ The authors declare no conflicts of interest.

۲۷۳ **Availability of Data and Materials**

۲۷۴ The data generated and/or analyzed during the current study are available from the corresponding
۲۷۵ author on request.

۲۷۶ **Acknowledgments**

۲۷۷ The authors wish to thank the Ferdowsi University of Mashhad for the laboratory support of this
۲۷۸ project.

۲۷۹

۲۸۰

۲۸۱ **Reference**

- ۲۸۲ 1. Kaufmann H, Medzhitov R, Gordon S. The Innate Immune Response to Infection. Washington, DC, USA:
۲۸۳ ASM Press. 2004. P. 324-450.

2. Coccolini C, Berselli E, Blanco-Llamero C. Biomedical and Nutritional Applications of Lactoferrin. *Int J Pept Res Ther.* 2023; 29, 71.
3. Ellass-Rochard E, Roseanu A, Legrand D, Trif M, Salmon V, Motas C, Montreuil J, Spik G. Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide. *Biochem J.* 1995; 15;312 (Pt 3)(Pt 3):839-45.
4. Ramírez-Rico G, Martínez-Castillo M, Avalos-Gómez C, de la Garza M. Bovine apo-lactoferrin affects the secretion of proteases in *Mannheimia haemolytica* A2. *Access Microbiol.* 2021; 25;3(10):000269.
5. Gu Y, Stansfeld PJ, Zeng Y, Dong H, Wang W, Dong C. Lipopolysaccharide is inserted into the outer membrane through an intramembrane hole, a lumen gate, and the lateral opening of LptD. *Structure.* 2015; 3;23(3):496-504.
6. Li J, Koh JJ, Liu S, Lakshminarayanan R, Verma CS, Beuerman RW. Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design. *Front Neurosci.* 2017; 14;11:73.
7. Vorland LH. Lactoferrin: a multifunctional glycoprotein. *Acta Pathologica, Microbiologica et Immunologica Scandinavica.* 1999;107(11):971-981.
8. Farnaud S, Evans RW. Lactoferrin—a multifunctional protein with antimicrobial properties. *Molecular Immunology.* 2003;40(7):395-405.
9. Zhang QY, Yan ZB, Meng YM. Antimicrobial peptides: mechanism of action, activity and clinical potential. *Military Med Res.* 2021;8, 48.
10. Hiltunen T, Virta M, Laine AL. Antibiotic resistance in the wild: an eco-evolutionary perspective. *Philos Trans R Soc Lond B Biol Sci.* 2017;372(1712):20160039.
11. Wang J, Dou X, Song J, Lyu Y, Zhu X, Xu L. Antimicrobial peptides: promising alternatives in the post feeding antibiotic era. *Med Res Rev.* 2019;39(3):831-59.
12. Assoni L, Milani B, Carvalho MR, Nepomuceno LN, Waz NT, Guerra MES, Converso TR, Darrieux M. Resistance Mechanisms to Antimicrobial Peptides in Gram-Positive Bacteria. *Front Microbiol.* 2020; 21;11:593215.
13. Pirtskhalava M, Vishnepolsky B, Grigolava M, Managadze G. Physicochemical Features and Peculiarities of Interaction of AMP with the Membrane. *Pharmaceuticals (Basel).* 2021 17;14(5):471.
14. Lyu Z, Yang P, Lei J, Zhao J. Biological Function of Antimicrobial Peptides on Suppressing Pathogens and Improving Host Immunity. *Antibiotics.* 2023; 12, 1037.
15. Wadhvani P, Epanand RF, Heidenreich N, Bürrck J, Ulrich AS, Epanand RM. Membrane-active peptides and the clustering of anionic lipids. *Biophys J.* 2012; 18;103(2):265-74.
16. Stark M, Liu LP, Deber CM. Cationic hydrophobic peptides with antimicrobial activity. *Antimicrob Agents Chemother.* 2002; 46(11):3585-90.
17. Lei J, Sun L, Huang S, Zhu C, Li P, He J, Mackey V, Coy DH, He Q. The antimicrobial peptides and their potential clinical applications. *Am J Transl Res.* 2019;15;11(7):3919-3931.
18. Kumar P, Kizhakkedathu JN, Straus SK. Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo. *Biomolecules.* 2018;19;8(1):4.
19. Paiva AD, Breukink E, Mantovani HC. Role of lipid II and membrane thickness in the mechanism of action of the lantibiotic bovicin HC5. *Antimicrob Agents Chemother.* 2011; 55(11):5284-93.
20. Oñate-Garzón J, Manrique-Moreno M, Trier S. Antimicrobial activity and interactions of cationic peptides derived from *Galleria mellonella* cecropin D-like peptide with model membranes. *J Antibiot.* 2017; 70, 238-245.
21. Hollmann A, Martínez M, Maturana P, Semorile LC, Maffia PC. Antimicrobial Peptides: Interaction With Model and Biological Membranes and Synergism With Chemical Antibiotics. *Front Chem.* 2018; 5;6:204.
22. Palmer N, Maasch JRMA, Torres MDT, de la Fuente-Nunez C. Molecular Dynamics for Antimicrobial Peptide Discovery. *Infect Immun.* 2021;17;89(4):e00703-20.
23. Śledź P, Cafflich A. Protein structure-based drug design: from docking to molecular dynamics. *Curr Opin Struct Biol.* 2018;48:93-102.
24. Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen MY, Pieper U, Sali A. Comparative protein structure modeling using Modeller. *Curr Protoc Bioinformatics.* 2006;Chapter 5:Unit-5.6.

25. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. *J. Appl. Cryst.* 1993;26, 283-291.
26. Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, Lindahl E. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. *SoftwareX.* 2015;1-2:19–25.
27. MacKerell AD Jr, Banavali N, Foloppe N. Development and current status of the CHARMM force field for nucleic acids. *Biopolymers.* 2000-2001;56(4):257-65.
28. Berendsen HJC, Postma JPM, van Gunsteren WF, Hermans J. Interaction Models for Water in Relation to Protein Hydration. In: Pullman, B. (eds) *Intermolecular Forces. The Jerusalem Symposia on Quantum Chemistry and Biochemistry.* 1981; vol 14. Springer, Dordrecht.
29. Nosé S, Klein ML. Constant pressure molecular dynamics for molecular systems, *Molecular Physics.* 1983;50:5, 1055-1076.
30. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE 3rd. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. *Acc Chem Res.* 2000;33(12):889-97.
31. Taghizadegan N, Firozrai M, Nassiri M, Ariannejad H. Use of Molecular Dynamic Tools in Engineering of Onconase Enzyme to Increase Cellular Uptake and Evade RI. *Int J Pept Res Ther.* 2020; 26, 737–743.
32. Schimek C, Egger E, Tauer C, Striedner G, Brocard C, Cserjan-Puschmann M, Hahn R. Extraction of recombinant periplasmic proteins under industrially relevant process conditions: Selectivity and yield strongly depend on protein titer and methodology. *Biotechnol Prog.* 2020;Sep;36(5):e2999.
33. Huang YC, Lin YM, Chang TW, Wu SJ, Lee S. The flexible and clustered lysine residues of human ribonuclease 7 are critical for membrane permeability and antimicrobial activity, *J BiolChem.* 2007;(282): 4626-4633.
34. Mercer DK, Torres MDT, Duay SS, Lovie E, Simpson L, von Köckritz-Blickwede M, de la Fuente-Nunez C, O'Neil DA, Angeles-Boza AM. Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy. *Front Cell Infect Microbiol.* 2020;7;10:326.
35. O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations: Review on antimicrobial resistance. 2016; 1–76.
36. El-Kafrawy SA, Abbas AT, Oelkrug C, Tahoon M, Ezzat S, Zumla A, Azhar EI. IgY antibodies: The promising potential to overcome antibiotic resistance. *Front Immunol.* 2023;20;14:1065353.
37. Bahar AA, Ren D. Antimicrobial peptides. *Pharmaceuticals (Basel)* 2013;6:1543–75.
38. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. *J Leukoc Biol.* 2004;75:39–48.
39. Lei J, Sun L, Huang S, Zhu C, Li P, He J, Mackey V, Coy DH, He Q. The antimicrobial peptides and their potential clinical applications. *Am J Transl Res.* 2019;15;11(7):3919-3931.
40. Phillips JC, Hardy DJ, Maia JDC, Stone JE, Ribeiro JV, Bernardi RC, Buch R, Fiorin G, Hénin J, Jiang W, McGreevy R, Melo MCR, Radak BK, Skeel RD, Singharoy A, Wang Y, Roux B, Aksimentiev A, Luthey-Schulten Z, Kalé LV, Schulten K, Chipot C, Tajkhorshid E. Scalable molecular dynamics on CPU and GPU architectures with NAMD. *J Chem Phys.* 2020; 153:044130.
41. Pourmousa M, Song HD, He Y, Heinecke JW, Segrest JP, Pastor RW. Tertiary structure of apolipoprotein A-I in nascent high-density lipoproteins. *Proc Natl Acad Sci U S A.* 2018;115:5163–5168.
42. Nguyen LT, Haney EF, Vogel HJ. The expanding scope of antimicrobial peptide structures and their modes of action. *Trends Biotechnol.* 2011; 29:464–472.
43. Koehbach J, Craik DJ. The vast structural diversity of antimicrobial peptides. *Trends Pharmacol Sci.* 2019; 40:517–528.
44. Torres MDT, Pedron CN, Araújo I, Silva PI, Silva FD, Oliveira VX. Decoralin analogs with increased resistance to degradation and lower hemolytic activity. *ChemistrySelect.* 2017; 2:18–23.
45. Potaman VN, Sinden RR. DNA: Alternative Conformations and Biology. In: *Madame Curie Bioscience Database [Internet].* Austin (TX). Landes Bioscience. 2000-2013; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK6545/>.
46. Fourie KR; Wilson HL. Understanding GroEL and DnaK Stress Response Proteins as Antigens for Bacterial Diseases. *Vaccines.* 2020; 8, 773.

- ३८१
३८२
३८३
३८४
३८५
३८६
३८७
३८८
३८९
३९०
३९१
३९२
३९३
३९४
३९५
३९६
३९७
३९८
३९९
४००
47. Shao X, Jiang M, Yu Z. Surface display of heterologous proteins in *Bacillus thuringiensis* using a peptidoglycan hydrolase anchor. *Microb Cell Fact.* 2009; 8, 48 (2009).
 48. Rizzetto G, Gambini D, Maurizi A, Molinelli E, De Simoni E, Pallotta F, Brescini L, Cirioni O, Offidani A, Simonetti O, Giacometti A. The sources of antimicrobial peptides against Gram-positives and Gram-negatives: our research experience. *Infez Med.* 2023;1;31(3):306-322.
 49. Sinha M, Kaushik S, Kaur P, Sharma S, Singh TP. Antimicrobial lactoferrin peptides: the hidden players in the protective function of a multifunctional protein. *Int J Pept.* 2013;2013:390230.
 50. Munk JK, Ritz C, Fliedner FP, Frimodt-Møller N, Hansen PR. Novel method to identify the optimal antimicrobial peptide in a combination matrix, using anoplins as an example. *Antimicrob Agents Chemother.* 2014;58(2):1063-70.
 51. Chen L, Shen T, Liu Y. Enhancing the antibacterial activity of antimicrobial peptide PMAP-37(F34-R) by cholesterol modification. *BMC Vet Res.* 2020;16, 419.
 52. Wiradharma N, Sng MYS, Khan M, Ong ZY, Yang YY. Rationally designed α -helical broad-spectrum antimicrobial peptides with idealized facial amphiphilicity. *Macromol Rapid Commun.* 2013;34(1):74–80.